Warfarin, vagy acenocoumarol? Melyik elonyösebb a krónikus pitvarfibrilláció antikoaguláns kezelésében?

Translated title of the contribution: Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A SPORTIF-III substudy. BACKGROUND: Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life. OBJECTIVE: The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A. METHODS: We compared prospectively a 3 months period on W with a 3 months period on A. RESULTS: The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6% for W and 56 +/- 26.8% for A (p <0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20%) than on A (19 +/- 19%), p <0,001. There was a good correlation between A and W doses (r = 0.65, p <0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78. CONCLUSIONS: 1. anticoagulation effect stability was superior for A compared to W; 2. W/A dose ratio was 2.18.

Original languageHungarian
Pages (from-to)2619-2621
Number of pages3
JournalOrvosi Hetilap
Volume145
Issue number52
Publication statusPublished - Dec 26 2004

Fingerprint

Acenocoumarol
International Normalized Ratio
Warfarin
Anticoagulants
Atrial Fibrillation
Half-Life
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Warfarin, vagy acenocoumarol? Melyik elonyösebb a krónikus pitvarfibrilláció antikoaguláns kezelésében? / Lengyel, M.

In: Orvosi Hetilap, Vol. 145, No. 52, 26.12.2004, p. 2619-2621.

Research output: Contribution to journalArticle

@article{c376645cbe014315a400259741378157,
title = "Warfarin, vagy acenocoumarol? Melyik elony{\"o}sebb a kr{\'o}nikus pitvarfibrill{\'a}ci{\'o} antikoagul{\'a}ns kezel{\'e}s{\'e}ben?",
abstract = "A SPORTIF-III substudy. BACKGROUND: Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life. OBJECTIVE: The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A. METHODS: We compared prospectively a 3 months period on W with a 3 months period on A. RESULTS: The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6{\%} for W and 56 +/- 26.8{\%} for A (p <0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20{\%}) than on A (19 +/- 19{\%}), p <0,001. There was a good correlation between A and W doses (r = 0.65, p <0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78. CONCLUSIONS: 1. anticoagulation effect stability was superior for A compared to W; 2. W/A dose ratio was 2.18.",
author = "M. Lengyel",
year = "2004",
month = "12",
day = "26",
language = "Hungarian",
volume = "145",
pages = "2619--2621",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "52",

}

TY - JOUR

T1 - Warfarin, vagy acenocoumarol? Melyik elonyösebb a krónikus pitvarfibrilláció antikoaguláns kezelésében?

AU - Lengyel, M.

PY - 2004/12/26

Y1 - 2004/12/26

N2 - A SPORTIF-III substudy. BACKGROUND: Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life. OBJECTIVE: The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A. METHODS: We compared prospectively a 3 months period on W with a 3 months period on A. RESULTS: The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6% for W and 56 +/- 26.8% for A (p <0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20%) than on A (19 +/- 19%), p <0,001. There was a good correlation between A and W doses (r = 0.65, p <0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78. CONCLUSIONS: 1. anticoagulation effect stability was superior for A compared to W; 2. W/A dose ratio was 2.18.

AB - A SPORTIF-III substudy. BACKGROUND: Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life. OBJECTIVE: The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A. METHODS: We compared prospectively a 3 months period on W with a 3 months period on A. RESULTS: The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6% for W and 56 +/- 26.8% for A (p <0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20%) than on A (19 +/- 19%), p <0,001. There was a good correlation between A and W doses (r = 0.65, p <0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78. CONCLUSIONS: 1. anticoagulation effect stability was superior for A compared to W; 2. W/A dose ratio was 2.18.

UR - http://www.scopus.com/inward/record.url?scp=14544300554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544300554&partnerID=8YFLogxK

M3 - Article

C2 - 15724697

AN - SCOPUS:14544300554

VL - 145

SP - 2619

EP - 2621

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 52

ER -